Intellia Therapeutics (NTLA)
(Delayed Data from NSDQ)
$20.76 USD
+0.74 (3.70%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $20.73 -0.03 (-0.14%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Price, Consensus and EPS Surprise
NTLA 20.76 +0.74(3.70%)
Will NTLA be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for NTLA based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for NTLA
Intellia (NTLA) to Report Q1 Earnings: What's in the Cards?
Earnings Preview: Intellia Therapeutics, Inc. (NTLA) Q1 Earnings Expected to Decline
NTLA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Intellia (NTLA) Begins Dosing in Phase III ATTR Amyloidosis Study
Intellia Therapeutics, Inc. (NTLA) Crossed Above the 50-Day Moving Average: What That Means for Investors
Intellia Therapeutics, Inc. (NTLA) Just Overtook the 20-Day Moving Average
Other News for NTLA
Cantor Fitzgerald healthcare analysts hold an analyst/industry conference call
First Week of June 21st Options Trading For Intellia Therapeutics (NTLA)
Tracking Cathie Wood's ARK Invest 13F Portfolio - Q1 2024 Update
Biotech Alert: Searches spiking for these stocks today
Intellia Therapeutics Welcomes New Principal Accounting Officer